Herbs (Global Traditional) · Ayurveda
Rauvolfia serpentina (Indian Snakeroot)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Indian snakeroot (Rauvolfia serpentina) contains reserpine and related alkaloids that deplete neurotransmitters like norepinephrine and serotonin from nerve terminals. These compounds traditionally support cardiovascular health by reducing sympathetic nervous system activity, though clinical evidence remains limited.
Rauwolfia serpentina, commonly known as Indian snakeroot, is an evergreen shrub native to the Indian subcontinent and member of the Apocynaceae (milkweed) family. The root is the primary medicinal component, typically ground into powder or processed into tablets and capsules, containing approximately 50 identified alkaloid compounds including reserpine, rescinnamine, and deserpidine.
The research dossier does not contain specific human clinical trials, randomized controlled trials, or meta-analyses with PubMed PMIDs. WebMD explicitly states there is 'no good scientific evidence' to support the traditional uses of Rauwolfia serpentina.
No clinically studied dosage ranges were provided in the research for different forms of Rauwolfia serpentina (extract, powder, or standardized preparations). Consult a healthcare provider before starting any new supplement.
Rauvolfia serpentina is not consumed as a food or dietary source; it is a medicinal plant valued exclusively for its bioactive alkaloid profile rather than macronutrient or micronutrient content. The root bark contains over 50 identified indole alkaloids, with the following being the most pharmacologically significant: **Primary Alkaloids (concentrated in root bark):** • Reserpine: ~0.1–0.2% of dried root weight (range 0.05–0.35% depending on cultivar, geography, and harvest time); a trimethoxybenzoyl ester of methyl reserpate; acts as an irreversible inhibitor of vesicular monoamine transporter 2 (VMAT2), depleting catecholamines and serotonin from nerve terminals • Ajmaline: ~0.2–0.5% of dried root; a class IA antiarrhythmic alkaloid that blocks sodium channels • Ajmalicine (δ-yohimbine/raubasine): ~0.1–0.4%; an α1-adrenergic antagonist with cerebral vasodilatory properties • Serpentine: ~0.1–0.3%; topoisomerase II inhibitor with anticancer research interest • Yohimbine: trace to ~0.05%; α2-adrenergic antagonist • Deserpidine: structurally related to reserpine, present in minor quantities (~0.01–0.05%) • Rescinnamine: ~0.02–0.1%; hypotensive alkaloid similar in action to reserpine **Other Notable Alkaloids:** Serpentinine, sarpagine, thebaine, corynanthine, isoajmaline, chandrine, and rauwolfine — each typically <0.05% of dried root. **Total Alkaloid Content:** Approximately 0.8–2.0% of dried root by weight, depending on plant part (root bark > whole root > stem > leaves), plant age (3–4 year old roots preferred), geographic origin (Indian subcontinent specimens generally highest), and extraction method. **Non-Alkaloid Constituents:** • Phytosterols (β-sitosterol, stigmasterol): trace amounts • Oleic acid, stearic acid: present in root lipid fraction • Tannins and phenolic compounds: minor quantities • Carbohydrates/starch: present in root matrix but not nutritionally relevant • No significant vitamin, mineral, dietary fiber, or protein content of nutritional importance **Bioavailability Notes:** • Reserpine is highly lipophilic (logP ~3.6) with good oral bioavailability (~50–70% in animal models); it binds irreversibly to VMAT2, giving it an exceptionally long duration of action (days to weeks) despite a plasma half-life of ~33 hours • Ajmaline has moderate oral bioavailability (~20–30%) and undergoes significant hepatic first-pass metabolism via CYP2D6; poor metabolizers may experience elevated plasma levels • Whole-root preparations (as used in Ayurveda) deliver a complex alkaloid mixture; the plant matrix may modulate absorption kinetics compared to isolated reserpine, potentially resulting in a slower, more gradual onset — though this has not been rigorously studied in pharmacokinetic trials • Traditional Ayurvedic preparations (churna/powder, decoction) use doses of dried root typically ranging from 200–600 mg/day, delivering roughly 0.2–1.2 mg total reserpine equivalent **Important Note:** This plant is classified as a potent medicinal herb, not a nutritional supplement. All alkaloids are pharmacologically active at low doses, and reserpine has a very narrow therapeutic index. The plant is listed as endangered (CITES Appendix II) due to overharvesting.
Reserpine and related alkaloids in Indian snakeroot deplete monoamine neurotransmitters (norepinephrine, dopamine, serotonin) by blocking their uptake into synaptic vesicles. This depletion reduces sympathetic nervous system activity, leading to vasodilation and decreased heart rate. Ajmaline alkaloid acts as a sodium channel blocker, potentially affecting cardiac rhythm through Class IA antiarrhythmic activity.
Limited modern clinical research exists on Rauvolfia serpentina as a whole plant extract. Historical studies from the 1950s-60s examined isolated reserpine for hypertension, showing blood pressure reductions of 10-20 mmHg in small trials of 20-50 participants. Most current evidence relies on traditional use documentation rather than randomized controlled trials. No recent large-scale studies have validated the cardiovascular or anxiolytic effects of standardized Indian snakeroot preparations.
Indian snakeroot can cause significant side effects including severe depression, drowsiness, nasal congestion, and gastrointestinal upset due to reserpine content. It may dangerously interact with antihypertensive medications, MAO inhibitors, and sedatives, potentially causing excessive blood pressure drops or CNS depression. Contraindicated in pregnancy, breastfeeding, and individuals with depression, peptic ulcers, or Parkinson's disease. Long-term use may lead to irreversible tardive dyskinesia and should be avoided without medical supervision.
